Retatrutide Side Effects: The Dose-by-Dose Numbers

Almost everything written about retatrutide side effects reports a single number per event, which is the least useful way to present this particular compound. Retatrutide's adverse event profile is almost entirely dose dependent, so a headline figure like "42 percent nausea" describes the 12mg arm and badly misrepresents what happens at 4mg, where the same event runs at 28.6 percent and discontinuation sits below placebo.

What follows is the profile broken out by dose, using the 80 week phase 3 data and the earlier phase 2 findings where they add something. The practical conclusion arrives early and holds throughout: on the published numbers, the dose you sit at matters more than any management strategy, and the top of the range buys very little extra effect for a substantially worse experience.

The Full Adverse Event Table by Dose

These are the rates from the 80 week phase 3 readout across the 4mg, 9mg and 12mg arms, with placebo for reference. Every figure is the proportion of participants reporting the event at least once over the full 80 weeks, not the proportion experiencing it at any given moment.

Two rows in that table are doing most of the work. Vomiting more than doubles between 4mg and 9mg, which is the steepest jump anywhere in the dataset. And discontinuation nearly triples across the range, from below placebo at 4mg to better than one in nine at 12mg.

The upper respiratory infection row is the useful control. It sits at 11.6 percent on placebo and between 12.2 and 14.2 percent on drug with no dose gradient at all, which is what an event unrelated to the compound looks like. When someone tells you their cold was caused by retatrutide, this row is the answer.

Gastrointestinal Effects: The Escalation Artefact

The GI events are not evenly distributed across the treatment period. They cluster tightly in the days following each dose increase and then fade as the body adapts to that level. This is why two people on identical protocols report completely different experiences: one is describing week 5, three days after stepping up, and the other is describing week 11 on a steady dose.

The phase 2 trial demonstrated this directly by testing two starting doses. Beginning at 2mg rather than 4mg partially mitigated the GI burden without changing where participants ended up, which is about as clean a result as escalation research produces. Slower is genuinely better tolerated, and it costs nothing but time.

Why constipation behaves differently

Nausea, vomiting and diarrhoea all climb steeply with dose. Constipation barely moves: 23.8 percent at 4mg against 26.1 percent at 12mg, a gap of just over two points across a tripling of the dose. That flatness suggests a different mechanism. Delayed gastric emptying and reduced intake are largely present once any meaningful dose is on board, and pushing higher does not slow the gut proportionally further.

It also means constipation is the one GI effect that will not resolve by holding a dose, because it was never an adaptation problem. Fluid and fibre intake fall in step with appetite, and that is the variable to address. The dosage guide covers escalation pacing in more detail.

Dysesthesia: The Phase 3 Surprise

Altered skin sensation, most often described as tingling, burning or heightened sensitivity to touch, appeared in 12.5 percent of the 12mg arm against 0.9 percent on placebo. That is a more than thirteen-fold difference and clearly a real drug effect.

What makes it notable is that it did not appear in phase 2 at all. It surfaced only when the trial population grew larger and the exposure ran longer, which is the classic signature of an event that is real but uncommon enough to hide in a few hundred participants. Reported cases were mostly mild to moderate, the majority resolved while dosing continued, and most participants who experienced it stayed in the trial.

The mechanism is not established. Glucagon receptor agonism is the obvious candidate simply because it is the component retatrutide has that tirzepatide and semaglutide do not, but that is an inference from the compound's structure rather than a demonstrated pathway. Anyone reading a confident explanation of why this happens is reading speculation.

Heart Rate: A Rise That Reverses

Heart rate increased in a dose dependent manner through roughly week 24, then declined at weeks 36 and 48 while participants continued dosing. The reversal while treatment continues is the important part. It points to a transient adaptation rather than a sustained cardiovascular effect, and the magnitude was broadly comparable to other incretin agonists.

That said, a transient effect is still an effect. Anyone with a history of arrhythmia, uncontrolled hypertension or existing cardiac disease has a genuine reason to want this supervised rather than self managed, because the window where heart rate is elevated runs for months rather than days.

Serious Events and the Discontinuation Picture

Serious adverse events in phase 2 ran 0 to 6 percent across the retatrutide arms against 4 percent on placebo, meaning some drug arms had fewer than placebo. Overall adverse event incidence was 73 to 94 percent on drug against 70 percent on placebo, a figure that sounds alarming until you notice that seven in ten people on placebo also reported an adverse event. Almost everyone in a long trial reports something.

The discontinuation numbers are the honest summary of tolerability, because they measure what people actually did rather than what they reported. At 4mg, 4.1 percent left for adverse events against 4.9 percent on placebo. At that dose, side effects were not what drove people out. At 12mg it was 11.3 percent, and that is the number worth carrying.

The 9mg versus 12mg trade

Weight loss at 80 weeks was 25.9 percent at 9mg and 28.3 percent at 12mg. That extra 2.4 points cost 4 points of nausea, 2.5 points of vomiting and a jump in discontinuation from 6.9 to 11.3 percent. By the 104 week extension the arms had converged further, at 29.5 versus 30.3 percent.

Put plainly: the top dose delivers under a point of additional loss by two years while roughly 60 percent more people abandon it. For most people the 9mg arm is the better endpoint, and the before and after page shows what those trajectories look like in practice.

Effects People Attribute to Retatrutide That Are Not Direct

Several complaints that get filed under side effects are downstream consequences of rapid weight loss rather than actions of the compound.

• Hair shedding. This is telogen effluvium triggered by the rate of loss, not a follicular drug effect, and it follows the trigger by two to four months. The full mechanism is covered here.
• Fatigue and cold intolerance. Predictable at a large caloric deficit regardless of what produced it.
• Muscle loss. A function of protein intake and resistance training during a deficit. Appetite suppression makes adequate protein harder, not impossible.
• Facial volume loss. Fat loss from a subcutaneous depot, visible because it is on the face.

The distinction is not pedantic. Effects caused by the compound respond to dose adjustment. Effects caused by the rate of loss respond to slowing the rate of loss, which sometimes means holding a dose rather than reducing it, and sometimes means eating more at the same dose. Confusing the two leads people to cut a dose that was not the problem.

How This Compares to Tirzepatide and Semaglutide

Retatrutide's GI profile is in the same family as the dual and single agonists, running somewhat higher at matched weight loss because the loss itself is faster. Dysesthesia is the one event without a clear counterpart in the older compounds, and the glucagon component is the structural difference that makes it plausible.

The comparison that matters is not event for event but effect per unit of discomfort. Tirzepatide against retatrutide and retatrutide against semaglutide both cover that trade in full. The short version is that retatrutide produces more loss and more side effects, and whether that is a good exchange depends entirely on which dose you are comparing at.

What the Numbers Do Not Cover

Every figure on this page comes from supervised trials using pharmaceutical grade material at verified concentrations, with clinicians monitoring and dosing errors caught early. None of those conditions hold for research chemical material bought online.

Two failure modes sit entirely outside the trial data. Concentration error means the dose someone believes they are taking is not the dose they took, which turns a careful escalation plan into a guess. The reconstitution guide exists because this is the most common avoidable mistake in the space. And material purity is unverifiable without a batch certificate of analysis, so an adverse reaction to an unknown contaminant will present as a retatrutide side effect and be recorded by the person as one.

Anyone assessing risk from the tables above should treat them as a floor rather than a full account. The main retatrutide guide and the general peptide side effects page cover the wider context.

Frequently Asked Questions

What are the most common retatrutide side effects?

Gastrointestinal events dominate. Nausea affected 28.6 percent at 4mg, 38.4 percent at 9mg and 42.4 percent at 12mg against 14.8 percent on placebo. Diarrhoea ran 25.2 to 34.1 percent, constipation 23.8 to 26.1 percent, and vomiting 10.6 percent at 4mg rising to 25.3 percent at 12mg. Nearly every one is dose dependent, which is the single most useful fact about the profile.

Does retatrutide raise heart rate?

Yes, and the pattern is unusual. Heart rate rose dose dependently through roughly week 24 and then declined at weeks 36 and 48 while dosing continued. The rise appears to be a transient adaptation rather than a sustained effect, and the magnitude is broadly in line with other incretin agonists. It is still the reason anyone with an arrhythmia history or uncontrolled hypertension should have this supervised.

What is dysesthesia and why does retatrutide cause it?

Dysesthesia is altered skin sensation, usually tingling, burning or heightened sensitivity to touch. It appeared in 5.1 percent at 4mg, 12.3 percent at 9mg and 12.5 percent at 12mg versus 0.9 percent on placebo. It did not surface in phase 2 at all and emerged only in the larger, longer phase 3 population. Cases were mostly mild to moderate, most resolved during treatment, and the mechanism is not established.

How many people stop retatrutide because of side effects?

Discontinuation for adverse events ran 4.1 percent at 4mg, 6.9 percent at 9mg and 11.3 percent at 12mg, against 4.9 percent on placebo. The 4mg figure sitting below placebo is worth noticing: at the low dose, tolerability was not what pushed people out. The dropout problem is specific to the top of the range.

Do retatrutide side effects go away?

The gastrointestinal ones largely do. They cluster in the days after each dose increase and fade as the body adapts to a given level, which is why the same person can be miserable in week 5 and untroubled in week 11 on a higher dose. Effects that persist unchanged for months, or begin long after the last escalation, are not following the expected course and deserve a different explanation.

Is 12mg worth the extra side effects over 9mg?

The trade is poor on the published numbers. Going from 9mg to 12mg added about 2.4 percentage points of weight loss at 80 weeks while nausea rose 4 points, vomiting rose 2.5 points and discontinuation rose from 6.9 to 11.3 percent. By 104 weeks the gap had narrowed to 29.5 versus 30.3 percent. The top dose buys a small amount of extra effect for a substantially worse experience.